Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2016-04-30
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
NCT03133741
Physiology of GIP(1-30)NH2 in Humans
NCT04792762
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT00732602
Effect of GIP After a Meal in Patients With Type 2 Diabetes
NCT03702660
Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)
NCT03013296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of four experimental days (A-D) with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A) GIP\[1-42\], B) GIP-A, C) GIP\[1-42\] + GIP-A, or D) saline (placebo).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Infusion of saline
Saline
Placebo
GIP(1-42)
Infusion of agonist, GIP(1-42)
GIP(1-42)
GIP receptor agonist
GIP-A
Infusion of GIP-A alone
GIP-A
GIP receptor antagonist
GIP-A + GIP(1-42)
Infusion of GIP-A and GIP(1-42)
GIP-A
GIP receptor antagonist
GIP(1-42)
GIP receptor agonist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GIP-A
GIP receptor antagonist
GIP(1-42)
GIP receptor agonist
Saline
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lærke Smidt Gasbjerg
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Filip K Knop, MD, PhD
Role: STUDY_DIRECTOR
UHGentofte, Center for Diabetes Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Diabetes Research
Copenhagen, Gentofte, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, Dela F, Vilsboll T, Holst JJ, Rosenkilde MM, Knop FK. GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2018 Feb;61(2):413-423. doi: 10.1007/s00125-017-4447-4. Epub 2017 Sep 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHG-CFD-GIPANTA-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.